Diagnostics revenue grew an impressive 38% due to the necessity of Covid-19 testing.
Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target.
Let's talk about what's happening right now to get this thing under control and what it will look like not that long from now.
The decline of the healthcare firm's stock offers the opportunity to sell out-of-the-money puts for an attractive premium.
The company is set to report earnings on Thursday.
It's not the merits of the deal from a long-term perspective I want to trade. It's the beat down of the stock from above $13 to under $11.
EXAS is likely to consolidate its recent gains.
A correction in the shares of the provider of Covid-19 tests appears to be over and a new uptrend is underway.
GDRX will not stay in a tight range for long.
I know that Trump's going to blunt our community mask initiative because who needs masks if it isn't a big deal if you are sick?